Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
Prolong Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:intendedUse |
treatment of anemia
treatment of sickle cell disease |
| gptkbp:mechanismOfAction |
oxygen transfer agent
|
| gptkbp:productType |
oxygen therapeutic
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
gptkb:investigational_drug
|
| gptkbp:bfsParent |
gptkb:Artificial_Blood
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sanguinate
|